SCHEMBL31168643

SCHEMBL31168643

COc1cc(F)cnc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.42
CHRNA4 P43681 4/20 0.42
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CHRNA7 P36544 2/20 0.38
PDGFRB P09619 2/20 0.37
PDGFRA P16234 2/20 0.37
PGK1 P00558 1/20 0.34
HTT P42858 1/20 0.34
BCL6 P41182 2/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
AURKA O14965 1/20 0.33
ENPP1 P22413 1/20 0.33
GAA P10253 1/20 0.33
NPBWR1 P48145 1/20 0.33
MCHR1 Q99705 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2122632 1.00 CHRNB2 (0.42) CHRNB2CHRNA4ALDH1A1KDM4ESMN1; SMN2
SCHEMBL31322863 0.81 GRM5 (0.35) CHRNB2CHRNA4
SCHEMBL10266615 0.81 GRM5 (0.35) CHRNB2CHRNA4
SCHEMBL27174393 0.79 KCNQ3 (0.37)
SCHEMBL25410559 0.78 CHRNB2 (0.44) CHRNB2CHRNA4ALDH1A1KDM4ESMN1; SMN2
SCHEMBL21446936 0.78 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2PDGFRBPDGFRA
SCHEMBL15472079 0.78 PIK3CA (0.41) ALDH1A1PDGFRBPDGFRAAURKA
SCHEMBL19088186 0.77 PDGFRB (0.38) ALDH1A1PDGFRBPDGFRAIDO1TDO2
SCHEMBL27759682 0.77 CHRNB2 (0.43) CHRNB2CHRNA4ALDH1A1KDM4ESMN1; SMN2
SCHEMBL13928210 0.77 CHRNB2 (0.43) CHRNB2CHRNA4ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727941-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2026-04-22 EP disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
WO-2024255885-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-12-19 WO disclosed
WO-2024216164-A1 N2-((5-HYDROXY)-2-PYRIDYL)-PYRIDINE-2,4-DIAMINE DERIVATIVES AS EHMT1/2 MODULATORS FOR THE TREATMENT OF CANCER TANGO THERAPEUTICS, INC. (US) 2024-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A CHRNB2 4496/4885CHRNA4 4278/4885ALDH1A1 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.